Sequence diversity of kappa light chains from patients with AL amyloidosis and multiple myeloma

References

• Buxbaum JN, Dispenzieri A, Eisenberg DS, et al. Amyloid nomenclature 2022: update, novel proteins, and recommendations by the international society of amyloidosis (ISA) nomenclature committee. Amyloid. 2022;29(4):213–219. Dec doi: 10.1080/13506129.2022.2147636.
   PubMed Web of Science ®Google Scholar
• Merlini G. AL amyloidosis: from molecular mechanisms to targeted therapies. Hematology Am Soc Hematol Educ Program. 2017;2017(1):1–12. doi: 10.1182/asheducation-2017.1.1.
   PubMed Web of Science ®Google Scholar
• Wechalekar AD, Schonland SO, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121(17):3420–3427. Apr 25 doi: 10.1182/blood-2012-12-473066.
   PubMed Web of Science ®Google Scholar
• Schroeder HW, Jr., Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S41–S52. doi: 10.1016/j.jaci.2009.09.046.
   PubMed Web of Science ®Google Scholar
• Hoehn KB, Fowler A, Lunter G, et al. The diversity and molecular evolution of B-cell receptors during infection. Mol Biol Evol. 2016;33(5):1147–1157. doi: 10.1093/molbev/msw015.
   PubMed Web of Science ®Google Scholar
• Lefranc MP, Lefranc G. Immunoglobulins or antibodies: IMGT(®) bridging genes, structures and functions. Biomedicines. 2020;8(9):319. doi: 10.3390/biomedicines8090319.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Lacy MQ, Dispenzieri A. Immunoglobulin light chain amyloidosis and the kidney. Kidney Int. 2002;61(1):1–9. doi: 10.1046/j.1523-1755.2002.00085.x.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-48–e548. Nov doi: 10.1016/S1470-2045(14)70442-5.
   PubMed Web of Science ®Google Scholar
• Salwender H, Bertsch U, Weisel K, et al. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. BMC Cancer. 2019;19(1):504. doi: 10.1186/s12885-019-5600-x.
   PubMed Web of Science ®Google Scholar
• Goldschmidt H, Mai EK, Bertsch U, et al. Elotuzumab in combination with lenalidomide, bortezomib, dexamethasone and autologous transplantation for Newly-Diagnosed multiple myeloma: results from the randomized phase III GMMG-HD6 trial. Blood. 2021;138(Supplement 1):486–486. doi: 10.1182/blood-2021-147323.
   PubMedGoogle Scholar
• Berghaus N, Schreiner S, Granzow M, et al. Analysis of the complete lambda light chain germline usage in patients with AL amyloidosis and dominant heart or kidney involvement. PLoS One. 2022;17(2):e0264407. doi: 10.1371/journal.pone.0264407.
   PubMed Web of Science ®Google Scholar
• Baur J, Berghaus N, Schreiner S, et al. Identification of AL proteins from 10 λ-AL amyloidosis patients by mass spectrometry extracted from abdominal fat and heart tissue. Amyloid. 2022; 30(1):27–37. doi: 10.1080/13506129.2022.2095618.
   PubMed Web of Science ®Google Scholar
• Huhn S. ELDA qASO-PCR for high sensitivity detection of tumor cells in bone marrow and peripheral blood. Method Mol Biol. 2018;1792:1–14.
   PubMedGoogle Scholar
• Bolotin DA, Poslavsky S, Mitrophanov I, et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat Methods. 2015;12(5):380–381. doi: 10.1038/nmeth.3364.
   PubMed Web of Science ®Google Scholar
• Retter I, Althaus HH, Münch R, et al. VBASE2, an integrative V gene database. Nucleic Acids Res. 2005;33(Database issue):D671–4. doi: 10.1093/nar/gki088.
   PubMedGoogle Scholar
• Duvaud S, Gabella C, Lisacek F, et al. Expasy, the swiss bioinformatics resource portal, as designed by its users. Nucleic Acids Res. 2021;49(W1):W216–w227. doi: 10.1093/nar/gkab225.
   PubMed Web of Science ®Google Scholar
• Howe KL, Achuthan P, Allen J, et al. Ensembl 2021. Nucleic Acids Res. 2021;49(D1):D884–d891. doi: 10.1093/nar/gkaa942.
   PubMed Web of Science ®Google Scholar
• Giudicelli V, Chaume D, Lefranc MP. IMGT/GENE-DB: a comprehensive database for human and mouse immunoglobulin and T cell receptor genes. Nucleic Acids Res. 2005; 33(Database issue):D256–61. doi: 10.1093/nar/gki010.
   PubMed Web of Science ®Google Scholar
• Consortium U. UniProt: the universal protein knowledgebase in 2023. Nucleic Acids Res. 2023; 51(D1):D523–d531.
   PubMed Web of Science ®Google Scholar
• Swindells MB, Porter CT, Couch M, et al. abYsis: integrated antibody sequence and structure-management, analysis, and prediction. J Mol Biol. 2017;429(3):356–364. 3 doi: 10.1016/j.jmb.2016.08.019.
   PubMed Web of Science ®Google Scholar
• Gasteiger E, Hoogland C, Gattiker A, et al. Protein identification and analysis tools on the ExPASy server. In: Walker JM, editor. The proteomics protocols handbook. Totowa, NJ: Humana Press; 2005. p. 571–607.
   Google Scholar
• Gupta R, Brunak S. Prediction of glycosylation across the human proteome and the correlation to protein function. Pac Symp Biocomput. 2002;7:310–322.
   Google Scholar
• Dittrich T, Bochtler T, Kimmich C, et al. AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis. Blood. 2017;130(5):632–642. doi: 10.1182/blood-2017-02-767475.
   PubMed Web of Science ®Google Scholar
• Comenzo RL, Zhang Y, Martinez C, et al. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood. 2001;98(3):714–720. doi: 10.1182/blood.v98.3.714.
   PubMed Web of Science ®Google Scholar
• Bellotti V, Mangione P, Merlini G. Review: immunoglobulin light chain amyloidosis–the archetype of structural and pathogenic variability. J Struct Biol. 2000; 130(2–3):280–289. doi: 10.1006/jsbi.2000.4248.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Larson DR, Rajkumar SV, et al. N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression. Leukemia. 2020;34(10):2749–2753. Oct doi: 10.1038/s41375-020-0940-8.
   PubMed Web of Science ®Google Scholar
• Hora M, Sarkar R, Morris V, et al. MAK33 antibody light chain amyloid fibrils are similar to oligomeric precursors. PLoS One. 2017;12(7):e0181799. doi: 10.1371/journal.pone.0181799.
   PubMed Web of Science ®Google Scholar
• Abraham RS, Geyer SM, Price-Troska TL, et al. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood. 2003;101(10):3801–3808. doi: 10.1182/blood-2002-09-2707.
   PubMed Web of Science ®Google Scholar
• Kourelis TV, Dasari S, Theis JD, et al. Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry. Blood. 2017;129(3):299–306. doi: 10.1182/blood-2016-10-743997.
   PubMed Web of Science ®Google Scholar
• Connors LH, Jiang Y, Budnik M, et al. Heterogeneity in primary structure, post-translational modifications, and germline gene usage of nine full-length amyloidogenic kappa1 immunoglobulin light chains. Biochemistry. 2007;46(49):14259–14271. doi: 10.1021/bi7013773.
   PubMed Web of Science ®Google Scholar
• Sternke-Hoffmann R, Pauly T, Norrild RK, et al. Widespread amyloidogenicity potential of multiple myeloma patient-derived immunoglobulin light chains. BMC Biol. 2023;21(1):21. doi: 10.1186/s12915-022-01506-w.
   PubMed Web of Science ®Google Scholar
• Poshusta TL, Sikkink LA, Leung N, et al. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis. PLoS One. 2009;4(4):e5169. doi: 10.1371/journal.pone.0005169.
   PubMed Web of Science ®Google Scholar
• Randles EG, Thompson JR, Martin DJ, et al. Structural alterations within native amyloidogenic immunoglobulin light chains. J Mol Biol. 2009;389(1):199–210. doi: 10.1016/j.jmb.2009.04.010.
   PubMed Web of Science ®Google Scholar
• Nevone A, Girelli M, Mangiacavalli S, et al. An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis. Leukemia. 2022;36(8):2076–2085. doi: 10.1038/s41375-022-01599-w.
   PubMed Web of Science ®Google Scholar